Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Dissecting the complex regulation of Mad4 in glioblastoma multiforme cells.
|
22895069 |
2012 |
Glioblastoma Multiforme
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Dissecting the complex regulation of Mad4 in glioblastoma multiforme cells.
|
22895069 |
2012 |
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Further examination of the samples for the JC virus regulatory region identified the presence of sequences identical to JC virus Mad-4 and JC virus W1 viral isolates in the tumor and the demyelinated regions.
|
11914404 |
2002 |
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Next, we performed RNA sequencing of the tumor sample and identified two in-frame fusion transcripts: MXD4-NUTM1 and ARL6-POT1.
|
30338611 |
2018 |
Round cell sarcoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Novel MXD4-NUTM1 fusion transcript identified in primary ovarian undifferentiated small round cell sarcoma.
|
30338611 |
2018 |
Leukoencephalopathy, Progressive Multifocal
|
0.010 |
Biomarker
|
disease |
BEFREE |
Sequencing of the JCV regulatory region from the lymphocytes of three patients revealed the prototype MAD-1 strain of JCV in one patient with PML, a MAD-4 strain in a second patient with PML, and a slightly modified MAD-4 strain in an HIV-1-positive patient without PML.
|
1316734 |
1992 |
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Sequencing of the viral control region determined the presence of JCPyV Mad-4 or JCPyV(CY) in these tumors.
|
12429619 |
2002 |
oligodendroglioma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
TCR sequence analysis of the oligodendroglioma showed a JCV rearranged structure not related to a known viral strain, while the astrocytoma and the ependymoma disclosed a JCV Mad-4 strain that is known to induce brain tumors in animals.
|
10746685 |
2000 |
Adult Oligodendroglioma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
TCR sequence analysis of the oligodendroglioma showed a JCV rearranged structure not related to a known viral strain, while the astrocytoma and the ependymoma disclosed a JCV Mad-4 strain that is known to induce brain tumors in animals.
|
10746685 |
2000 |
Childhood Oligodendroglioma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
TCR sequence analysis of the oligodendroglioma showed a JCV rearranged structure not related to a known viral strain, while the astrocytoma and the ependymoma disclosed a JCV Mad-4 strain that is known to induce brain tumors in animals.
|
10746685 |
2000 |
Well Differentiated Oligodendroglioma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
TCR sequence analysis of the oligodendroglioma showed a JCV rearranged structure not related to a known viral strain, while the astrocytoma and the ependymoma disclosed a JCV Mad-4 strain that is known to induce brain tumors in animals.
|
10746685 |
2000 |
Astrocytoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
TCR sequence analysis of the oligodendroglioma showed a JCV rearranged structure not related to a known viral strain, while the astrocytoma and the ependymoma disclosed a JCV Mad-4 strain that is known to induce brain tumors in animals.
|
10746685 |
2000 |
Childhood Astrocytoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
TCR sequence analysis of the oligodendroglioma showed a JCV rearranged structure not related to a known viral strain, while the astrocytoma and the ependymoma disclosed a JCV Mad-4 strain that is known to induce brain tumors in animals.
|
10746685 |
2000 |
Ependymoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
TCR sequence analysis of the oligodendroglioma showed a JCV rearranged structure not related to a known viral strain, while the astrocytoma and the ependymoma disclosed a JCV Mad-4 strain that is known to induce brain tumors in animals.
|
10746685 |
2000 |
Adult Ependymoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
TCR sequence analysis of the oligodendroglioma showed a JCV rearranged structure not related to a known viral strain, while the astrocytoma and the ependymoma disclosed a JCV Mad-4 strain that is known to induce brain tumors in animals.
|
10746685 |
2000 |
Newly Diagnosed Childhood Ependymoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
TCR sequence analysis of the oligodendroglioma showed a JCV rearranged structure not related to a known viral strain, while the astrocytoma and the ependymoma disclosed a JCV Mad-4 strain that is known to induce brain tumors in animals.
|
10746685 |
2000 |
Childhood Ependymoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
TCR sequence analysis of the oligodendroglioma showed a JCV rearranged structure not related to a known viral strain, while the astrocytoma and the ependymoma disclosed a JCV Mad-4 strain that is known to induce brain tumors in animals.
|
10746685 |
2000 |
Brain Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
TCR sequence analysis of the oligodendroglioma showed a JCV rearranged structure not related to a known viral strain, while the astrocytoma and the ependymoma disclosed a JCV Mad-4 strain that is known to induce brain tumors in animals.
|
10746685 |
2000 |
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
TCR sequence analysis was possible in four cases and identified three Mad-4 and one type II sequences; the TCR genomic structures of JCV isolated from cerebrospinal fluid were the same as those sequenced from corresponding tumour tissue, thus indicating a possible cerebrospinal fluid dissemination of neoplastic cells carrying viral DNA.
|
14506971 |
2003 |
Sarcoma, Spindle Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two novel fusion partners were identified: MGA in two sarcomas (myxoid spindle cell sarcoma and undifferentiated sarcoma) (2/24 cases 8.3%) and MXD4 in a round cell sarcoma in the cecum (1/24 cases 4.2%).
|
30723300 |
2019 |
Undifferentiated (Embryonal) Sarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two novel fusion partners were identified: MGA in two sarcomas (myxoid spindle cell sarcoma and undifferentiated sarcoma) (2/24 cases 8.3%) and MXD4 in a round cell sarcoma in the cecum (1/24 cases 4.2%).
|
30723300 |
2019 |
Round cell sarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Two novel fusion partners were identified: MGA in two sarcomas (myxoid spindle cell sarcoma and undifferentiated sarcoma) (2/24 cases 8.3%) and MXD4 in a round cell sarcoma in the cecum (1/24 cases 4.2%).
|
30723300 |
2019 |